ID23299A - Formulasi-formulasi farmasi - Google Patents

Formulasi-formulasi farmasi

Info

Publication number
ID23299A
ID23299A IDP990444D ID990444D ID23299A ID 23299 A ID23299 A ID 23299A ID P990444 D IDP990444 D ID P990444D ID 990444 D ID990444 D ID 990444D ID 23299 A ID23299 A ID 23299A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
IDP990444D
Other languages
English (en)
Inventor
Cristi Bell-Huff
Thomas Francis Dolan
Angela Carol Gatlin Hausberger
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID23299A publication Critical patent/ID23299A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicon Polymers (AREA)
IDP990444D 1998-05-15 1999-05-14 Formulasi-formulasi farmasi ID23299A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8564698P 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
ID23299A true ID23299A (id) 2000-04-05

Family

ID=22193027

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP990444D ID23299A (id) 1998-05-15 1999-05-14 Formulasi-formulasi farmasi

Country Status (32)

Country Link
US (1) US20020002172A1 (id)
EP (1) EP0960621A3 (id)
JP (1) JPH11349483A (id)
KR (1) KR19990088249A (id)
CN (1) CN1251758A (id)
AP (1) AP9901534A0 (id)
AR (1) AR016481A1 (id)
AU (1) AU753478B2 (id)
BG (1) BG103396A (id)
BR (1) BR9902086A (id)
CA (1) CA2272042A1 (id)
CO (1) CO5060503A1 (id)
DZ (1) DZ2786A1 (id)
EA (1) EA002830B1 (id)
GT (1) GT199900061A (id)
HN (1) HN1999000066A (id)
HR (1) HRP990144A2 (id)
HU (1) HUP9901606A2 (id)
ID (1) ID23299A (id)
IS (1) IS5046A (id)
MA (1) MA26629A1 (id)
NO (1) NO992339L (id)
NZ (1) NZ335772A (id)
OA (1) OA11040A (id)
PA (1) PA8472901A1 (id)
PE (1) PE20000546A1 (id)
PL (1) PL333118A1 (id)
SG (1) SG79255A1 (id)
SK (1) SK61599A3 (id)
TR (1) TR199901077A2 (id)
YU (1) YU21999A (id)
ZA (1) ZA993338B (id)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1120120A4 (en) * 1998-10-05 2009-04-29 Eisai R&D Man Co Ltd TABLETS DISSOLVING DIRECTLY IN MOUTH
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
AU3744800A (en) * 1999-03-16 2000-10-04 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
ES2381862T3 (es) 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
IN192750B (id) * 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6544552B2 (en) * 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
CA2449163C (en) * 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
CA2460894A1 (en) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co., Ltd. Press-coated fast-dissolving/disintegrating molded product
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
JP4922762B2 (ja) * 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
AU2006299232A1 (en) * 2005-09-29 2007-04-12 Bayer Schering Pharma Aktiengesellschaft PDE inhibitors and combinations thereof for the treatment of urological disorders
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
PL2114147T3 (pl) * 2007-02-12 2012-10-31 Vyrix Pharmaceuticals Inc Zmniejszanie skutków ubocznych tramadolu
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
FR2932682B1 (fr) * 2008-06-23 2013-07-12 Bionetwork Nouvelles formes pharmaceutiques a effet rapide et les utilisations des compositions pharmaceutiques ainsi obtenus.
WO2010104563A2 (en) 2009-03-09 2010-09-16 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
DE102009016584A1 (de) 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2338474A1 (de) 2009-12-23 2011-06-29 Ratiopharm GmbH Oral dispersible Tablette enthaltend kompaktierte Sildenafil-Base
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
CN103402504B (zh) * 2011-02-11 2015-10-14 西梯茜生命工学股份有限公司 包含西地那非游离碱的膜制剂及其生产方法
KR101418406B1 (ko) * 2011-08-24 2014-07-10 한미약품 주식회사 실데나필 유리 염기를 포함하는 구강 붕해정
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN105769887B (zh) * 2014-12-23 2019-04-30 上海复星星泰医药科技有限公司 一种复方果糖二磷酸钠果糖口崩片及其制备方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN114246835A (zh) * 2022-01-05 2022-03-29 河北龙海药业有限公司 一种枸橼酸西地那非口腔崩解片的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE19532142A1 (de) * 1995-08-31 1997-03-06 Siemens Ag Verfahren und Vorrichtung zur Regelung eines vierdimensionalen Vektors einer Strecke mittels eines wertediskreten Stellgliedes mit begrenzter Schaltfrequenz
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
AU3744800A (en) * 1999-03-16 2000-10-04 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration

Also Published As

Publication number Publication date
MA26629A1 (fr) 2004-12-20
DZ2786A1 (fr) 2003-12-01
TR199901077A3 (tr) 1999-12-21
CO5060503A1 (es) 2001-07-30
JPH11349483A (ja) 1999-12-21
OA11040A (en) 2003-01-01
HRP990144A2 (en) 2000-02-29
EP0960621A3 (en) 2000-01-05
ZA993338B (en) 2000-11-14
NO992339D0 (no) 1999-05-14
EA002830B1 (ru) 2002-10-31
IS5046A (is) 1999-11-16
TR199901077A2 (en) 1999-12-21
BR9902086A (pt) 2000-05-02
US20020002172A1 (en) 2002-01-03
CA2272042A1 (en) 1999-11-15
HU9901606D0 (en) 1999-07-28
HN1999000066A (es) 1999-09-29
PA8472901A1 (es) 2000-09-29
SK61599A3 (en) 2000-12-11
EA199900373A2 (ru) 1999-12-29
EA199900373A3 (ru) 2000-08-28
CN1251758A (zh) 2000-05-03
SG79255A1 (en) 2001-03-20
EP0960621A2 (en) 1999-12-01
KR19990088249A (ko) 1999-12-27
GT199900061A (es) 2000-10-14
YU21999A (sh) 2002-03-18
NZ335772A (en) 2000-12-22
AU753478B2 (en) 2002-10-17
HUP9901606A2 (en) 2002-09-28
AP9901534A0 (en) 1999-06-30
NO992339L (no) 1999-11-16
PL333118A1 (en) 1999-11-22
BG103396A (bg) 2000-01-31
PE20000546A1 (es) 2000-07-07
AU2812699A (en) 1999-11-25
AR016481A1 (es) 2001-07-04

Similar Documents

Publication Publication Date Title
NO992339L (no) Farmasöytiske formuleringer
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
ID27415A (id) Komposisi farmaseutik
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
NO20005913D0 (no) Legemiddelsammensetning
NO20012915L (no) Ny farmasöytisk formulering
ID24654A (id) Formulasi farmasi omeprazola
PT1130966E (pt) Formulacoes antiparasitarias
MA24473A1 (fr) Formulations
ID29262A (id) Komposisi farmasi
DK1466615T3 (da) Farmaceutisk præparat
NO20015670L (no) Forbedrede farmasöytiske formuleringer
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
ID27201A (id) Komposisi farmasi
IS6398A (is) Lyfjablöndur
ID16781A (id) Formulasi-formulasi farmasi
EE9900440A (et) Farmatseutilised kompositsioonid
ID30032A (id) Formulasi farmasi
EE200000330A (et) Farmatseutilised kompositsioonid
EE200000459A (et) Farmatseutilised kompositsioonid
NO994436D0 (no) Farmasöytiske sammensetninger
SE9803952D0 (sv) Pharmaceutical formulation